CRSP - Crispr Therapeutics: Lucrative Partnerships And Promising Data Increase Its Appeal
- CRISPR Therapeutics' clinical programs are progressing nicely, showing excellent safety and efficacy, validating the prospects of its novel technology as a disruptive force in the biotech industry.
- Directionally, we see CRSP focusing on next-generation CAR-T and regenerative therapies for diseases with robust prevalence, increasing the chances of commercial success.
- CRSP's partnerships provided it with the cash it needs to continue developing its promising technology without the need to issue more shares or forgo significant revenue potential or patent assets.
For further details see:
Crispr Therapeutics: Lucrative Partnerships And Promising Data Increase Its Appeal